ArticleWellcome open research2021
There is no market for new antibiotics: this allows an open approach to research and development.
Article in Wellcome open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The 3D Value Framework for Sustainable Access to Effective Antibiotics.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- The pharmaceutical industry's multifaceted role in neglected tropical disease control: from market failure to global health innovation.Tropical medicine and health · 2026Review
- Phytochemical Quorum-Sensing Inhibitors Against Bacterial Pathogens: Mechanisms of Action and Translational Challenges.Current issues in molecular biology · 2026Review
- Exploring the perspectives of antimicrobial stewardship pharmacists in England on the subscription model for antimicrobial drugs.JAC-antimicrobial resistance · 2026Article
- Droplet microfluidics strategies for overcoming bottlenecks in antibiotics discovery.iScience · 2026Review
- The Capability Approach and Upstream Causes-A Discussion of Johnson's Ethical Evaluation Framework for Coercive Antimicrobial Stewardship Policies.Public health ethics · 2025Article
- "Dusting Off the Cobwebs": Rethinking How We Use New Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Infectious Keratitis Management: 10-Year Update.Journal of clinical medicine · 2025Review
- Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.npj antimicrobials and resistance · 2025Review
- Rational design of synthetic antimicrobial peptides based on the Escherichia coli ShoB toxin.Scientific reports · 2025Article
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
- Electrophysiological Insights into Antibiotic Translocation and Resistance: The Impact of Outer Membrane Proteins.Membranes · 2024Review
- New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Crowdsourcing for mining new fungal sources for addressing the need for novel antibiotics against multidrug resistant pathogens.The Journal of antibiotics · 2024Article
- Combatting Antibiotic Resistance: Regulatory Exclusivities for New Antibiotic Development in the United States and Europe.Infectious diseases & immunity · 2024Review
- Pull me - push you? The disparate financing mechanisms of drug research in global health.Globalization and health · 2024Article
- Using the Zebrafish Larval Model of Infection to Investigate Antibiotic Efficacy and Combination Treatments Against Staphylococcus aureus.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Visualization of Engineered M13 Phages Bound to Bacterial Targets by Transmission Electron Microscopy.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Plant-based compositions for the treatment of local and topical bacterial infections: a patent review.Future microbiology · 2024Review
- Open Source Antibiotics: Simple Diarylimidazoles Are Potent against Methicillin-ResistantACS infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent economic problem when it comes to developing such medicines. The problem stems from the perceived need for a "market" to drive commercial antibiotic development. In this article, we explore abandoning the market as a prerequisite for successful antibiotic research and development. Once one stops trying to fix a market model that has stopped functioning, one is free to carry out research and development (R&D) in ways that are more openly collaborative, a mechanism that has been demonstrably effective for the R&D underpinning the response to the COVID pandemic. New "open source" research models have great potential for the development of medicines for areas of public health where the traditional profit-driven model struggles to deliver. New financial initiatives, including major push/pull incentives, aimed at fixing the broken antibiotics market provide one possible means for funding an openly collaborative approach to drug development. We argue that now is therefore the time to evaluate, at scale, whether such methods can deliver new medicines through to patients, in a timely manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.